NADAC acquisition cost data for ACETAZOLAMIDE 125 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 51991088401 | $0.1437 | 2022-07-20 | Rx |
| 51991088401 | $0.1437 | 2022-07-20 | Rx |
| 23155028701 | $0.1430 | 2022-12-21 | Rx |
| 51672402201 | $0.1430 | 2022-12-21 | Rx |
| 52817020010 | $0.1430 | 2022-12-21 | Rx |
| 64380083306 | $0.1430 | 2022-12-21 | Rx |
| 70756072011 | $0.1430 | 2022-12-21 | Rx |
| 70954003330 | $0.1430 | 2022-12-21 | Rx |
| 71930000812 | $0.1430 | 2022-12-21 | Rx |
| 72888004701 | $0.1430 | 2022-12-21 | Rx |
Generic: Acetazolamide | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $18.9M | 187,883 | 88,880 | $1.55 |
| 2020 | $17.8M | 159,595 | 66,492 | $1.51 |
| 2021 | $14.9M | 186,468 | 76,184 | $1.08 |
| 2022 | $15.5M | 212,386 | 86,171 | $1.00 |
| 2023 | $14.8M | 223,297 | 90,681 | $0.9129 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Florida | $1.5M | 20,585 | 9,152 |
| California | $1.4M | 22,969 | 11,819 |
| New York | $1.2M | 17,242 | 6,593 |
| Texas | $975.6K | 17,007 | 7,752 |
| Pennsylvania | $782.4K | 11,200 | 3,768 |
| Illinois | $595.6K | 8,642 | 3,510 |
| Ohio | $508.9K | 7,377 | 2,903 |
| Michigan | $492.9K | 6,786 | 2,689 |
| North Carolina | $456.4K | 6,306 | 2,463 |
| South Carolina | $419.1K | 5,559 | 1,778 |
| New Jersey | $408.8K | 6,275 | 2,556 |
| Massachusetts | $381.9K | 5,771 | 2,237 |
| Tennessee | $381.8K | 4,772 | 1,758 |
| Georgia | $371.1K | 6,056 | 2,400 |
| Indiana | $350.0K | 5,233 | 1,768 |
| Louisiana | $303.7K | 4,912 | 1,766 |
| Puerto Rico | $271.6K | 3,764 | 1,506 |
| Missouri | $268.9K | 3,851 | 1,526 |
| Alabama | $260.7K | 3,139 | 1,179 |
| Washington | $243.4K | 3,654 | 1,697 |
| Virginia | $243.1K | 3,690 | 1,716 |
| Arizona | $237.2K | 3,726 | 1,809 |
| Wisconsin | $236.5K | 4,125 | 1,882 |
| Connecticut | $215.6K | 2,967 | 1,164 |
| Minnesota | $201.1K | 2,914 | 1,393 |
| Kentucky | $189.7K | 2,832 | 976 |
| Maryland | $166.4K | 2,753 | 1,442 |
| Colorado | $162.7K | 2,789 | 1,251 |
| Arkansas | $157.4K | 2,224 | 771 |
| Mississippi | $157.4K | 2,650 | 1,032 |
| Iowa | $139.7K | 2,574 | 774 |
| Oregon | $129.8K | 2,005 | 937 |
| Oklahoma | $92.0K | 1,378 | 649 |
| Kansas | $87.5K | 1,492 | 737 |
| West Virginia | $76.3K | 1,273 | 408 |
| New Hampshire | $74.4K | 1,033 | 438 |
| Nevada | $72.6K | 1,163 | 502 |
| Nebraska | $71.8K | 1,236 | 378 |
| Utah | $69.9K | 1,183 | 464 |
| Idaho | $69.9K | 1,046 | 383 |
| Maine | $66.8K | 704 | 296 |
| Hawaii | $62.6K | 780 | 347 |
| New Mexico | $62.5K | 856 | 385 |
| South Dakota | $43.2K | 730 | 187 |
| Delaware | $40.5K | 514 | 210 |
| North Dakota | $36.6K | 733 | 271 |
| Rhode Island | $33.0K | 584 | 259 |
| Montana | $32.0K | 568 | 184 |
| District of Columbia | $29.9K | 494 | 260 |
| Vermont | $27.3K | 318 | 162 |
| Wyoming | $22.9K | 296 | 88 |
| Alaska | $10.6K | 266 | 129 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.